Aurobindo Pharma

Motilal Oswal retains 'Buy' on Aurobindo Pharma as FY26-28 prospects shine

Tushar Manudhane, Vipul Mehta, and Eshita Jain, research analysts at MOFSL, value Aurobindo Pharma at 16 times 12-month forward earnings, assigning a target price of ₹1,430

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Nifty, Bank Nifty outlook; Shriram Fin, Ashok Leyland among top stock picks

On the daily chart, Nifty formed a bearish candle and continues to maintain a sequence of lower highs and lower lows for the fourth straight session indicating sustained pressure

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Stocks to Watch today, Nov 24: HUL, TCS, RVNL, HG Infra, Marico

Stocks to Watch today, November 24, 2025: From RVNL to HUL, here is a list of stocks that will be on investors' and traders' radar

Aurobindo incurring loss at China Plant, hopes to achieve break-even by Q4

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.

Q2FY26 results in line; Aurobindo Pharma could gain 25%, says Nuvama

According to Nuvama, Aurobindo's Q2FY26 revenue and Ebitda were ahead of consensus estimates by 2 per cent and 1 per cent, respectively, though PAT missed expectations by about 5 per cent

Q2 results today: Britannia, Inox, Zydus Wellness among 118 firms

Q2FY26 company results: Firms including Aurobindo Pharma, Muthoot Microfin, Delhivery, Blue Star, and Eureka Industries are also to release their July-September earnings reports today

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Fire at Aurobindo Pharma's Andhra unit halts production temporarily

Aurobindo Pharma on Friday said a fire accident at Unit-IV of its wholly-owned arm APL Healthcare Ltd at Naidupeta in Andhra Pradesh has resulted in production disruption temporarily. In a regulatory filing, the company said on September 18, 2025, at around 8:50 am, a small fire incident occurred in granulation area-10 of Unit IV of APL Healthcare, situated at Naidupeta, Andhra Pradesh (SEZ Unit), due to a short circuit. The fire spread to a panel, affecting granulation area-10 and causing partial damage to granulation area-8. Out of the total 19 lines in the said Unit, 2 lines have been impacted for about two weeks, it added. The fire incident was immediately controlled through the in-house fire hydrant team, along with support from external fire tenders, and there were no casualties or injuries, the company said. "The incident resulted in a temporary production impact estimated at about 3 per cent of the monthly capacity of the said unit. Necessary steps have been initiated for .

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Stocks to Watch, Aug 21: India Cements, Clean Science, Railtel, Aurobindo

Stocks to Watch today, August 21, 2025: From India Cements to Clean Science and Technology, here are a few stocks that investors and traders will eye; check the full list

Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva

Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal

Stocks to Watch, Aug 18: Vi, Glenmark Pharma, BPCL, NTPC, M&M, PVR Inox

Stocks to Watch today, August 18, 2025: From Vodafone Idea to BPCL, here is a list of stocks that will be on investors' and traders' radar

Aurobindo Pharma expects China plant to break even at Ebitda level in FY26

Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to

Stocks to Watch today, Aug 5: IndusInd Bank, DLF, Aurobindo Pharma, Bosch

Stocks to Watch today, August 5, 2025: DLF, Aurobindo Pharma, IndusInd Bank, Bosch, and Inox India are some of the key stocks to watch today

Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter last year

Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT due to lower API sales and US market revenue, while its European and growth markets continue to show positive momentum